Quick Answer
Artiva Biotherapeutics, Inc. reported Operating Income Loss of -$89.81 million for the year ending 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -33.5% in Operating Income Loss from 2024 to 2025.
- This data is from Artiva Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: -$11.82 million | Q3 2023: $10.81 million | Q1 2024: -$14.49 million | Q2 2024: -$16.19 million | Q3 2024: -$18.34 million | Q1 2025: -$22.17 million | Q2 2025: -$22.81 million | Q3 2025: -$22.90 million.
- Over the full 3 years of available data (2023 to 2025), Artiva Biotherapeutics, Inc.'s Operating Income Loss has declined by 192.8%.
- Historical annual values: Fiscal year 2025: -$89.81 million | Fiscal year 2024: -$67.28 million | Fiscal year 2023: -$30.67 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: